JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan

OPIR Senior Research Fellows Minoru Ito (left) and Shinichiro Iida With more than 70% of medicines approved in the US and Europe remaining unapproved in Japan, the think tank arm of the Japan Pharmaceutical Manufacturers Association (JPMA) is looking into...read more